News

This video showcases the Bleeding Disorders Research Collaborative (BDRC), a groundbreaking initiative led by the National Bleeding Disorders Foundation to transform research…

The National Bleeding Disorders Foundation (NBDF) is launching Educate to Elevate, a multi-year initiative to raise public awareness, educate communities, and improve healthcare…

At the 2025 Chapter Leadership Summit (CLS), the National Bleeding Disorders Foundation (NBDF) celebrated the generosity of chapter contributions to research.  For…

The three new recommendations concern off-label use for emicizumab for acquired hemophilia A; the use of anti-tissue factor pathway Inhibitors in hemophilia;…

BioMarin has decided to pursue allowing another company to market and sell ROCTAVIAN, its one-time gene therapy used to treat adults with…

Join us for an educational program about Hemlibra at GLHF’s new office, 12700 W. Bluemound Rd., Suite 130, Elm Grove, on Tuesday,…

The U.S. FDA approved Takeda’s supplemental Biologics License Application (sBLA) for Von Vendi, to expand its indication for routine prophylaxis to reduce…

Nearly 400 people with hemophilia joined gene therapy trials, and shared their data to help future generations. The WFH Gene Therapy Registry…

Mim8 (denecimig) is an injection therapy for preventing bleeds in people with hemophilia A with or without inhibitors. Antibody-based, Mim8 is designed…

Gene therapy has received some doubtful news: not about its effectiveness, but about cost and slow acceptance. Here’s some good news: two…

A new pilot study reveals how social determinants of health disproportionately affect underserved groups — including Black, Indigenous, and Hispanic/Latino individuals —…

Star Therapeutics has raised $125 million to propel the development of VGA039, a subcutaneous monoclonal antibody targeting Protein S. This investigational therapy…

Novo Nordisk has filed for FDA approval of denecimig (Mim8), an investigational subcutaneous therapy designed to treat people with hemophilia A with…

In this webinar, you’ll learn about the gaps that exist in modern research, and how Community Voices in Research uses lived experiences…

NBDF’s Pathway to Cures is investing in cutting edge technology and new approaches to bleeding disorders therapies. Learn more about Be Biopharma,…

Tax credits that were created as part of the ACA to help people afford their insurance were increased in 2022 are slated…

The FDA has expanded the indication for VONVENDI, a recombinant von Willebrand factor replacement therapy. It is now approved for prophylactic treatment…

Dedicated advocacy work by the World Federation of Hemophilia (WFH) has resulted in crucial changes to the World Health Organization (WHO) Essential…

Do you know the full range of therapy choices for you or your loved one? Read a great summary of information presented…

According to a study published in Haemophilia, patients with hemophilia face heightened risks of depression and anxiety due to pain and joint issues,…

The U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) injection (60 mg, 150 mg, or 300 mg) as a once-daily…

Be Biopharma announced that a first participant was dosed in the BeCoMe-9 Trial of BE-101for hemophilia B. BE-101 is a first-in-class, engineered…

Twenty-one states have filed suit to block implementation of the Marketplace Integrity Rule, arguing that it will create barriers to coverage and…

Women and girls with bleeding disorders face delays in diagnosis and care. Learn how research and community voices are changing the future…